Annabelle Fowler (@AbelleFowler) header
Annabelle Fowler (@AbelleFowler) profile picture

Life Sciences Consultant at Charles River Associates | Previously @US_FDA | Health Econ PhD via @Harvard & @HMSHCP | Se habla español

Providence, RI
Joined January 2010
Photo by Annabelle Fowler (@AbelleFowler)Photo by Annabelle Fowler (@AbelleFowler)
📢 New work with @US_FDA colleagues 📢 We looked at products that used the Competitive Generic Therapy (CGT) pathway to come to market. CGT includes designation and possible exclusivity, but it's not your typical 180-day exclusivity. CGT exclusivity is use it or lose it.
Study describes the characteristics and outcomes of products that have sought Competitive Generic Therapy designation and exclusivity ja.ma/3H7V3z2
1
2
This feature appears to be linked to swift commercialization: we observed entry for 86% of generics eligible for CGT X, with a median time-to-market of 2.5 days (1 day excluding complex products). Neat implications for the design of provisions to increase drug competition.
1
I had a terrific time discussing my work and experiences as an @ORISEaspire Fellow at @US_FDA. Thanks for having me, @HarvardMIT_CRS and TGP!
Our next #RegSci2021 Early Career Seminar on April 29th features recent @Harvard @HMSHCP health economics PhD graduate and current Public Health and Regulatory Research Fellow at @US_FDA, Dr. @AbelleFowler! RSVP here: eventbrite.com/e/regsci-earl…
2
2
12
Annabelle Fowler retweeted
Our research on public opinions about gender equality across 17 countries is out! It is a privilege to have been part of the team that lead this work at @WomenDeliver alongside @_Focus2030. Follow the link to explore the findings: lnkd.in/eb-7wAs vimeo.com/502550126
1
1
7
I'm happy to announce that I defended my dissertation last week! I'm grateful to my dream team committee: Tom McGuire, @Cutler_econ, @JMichaelMcW and @arieldora. Next up: starting as an ORISE Fellow in the Office of the @FDACommissioner, @US_FDA. Can't wait!
18
1
3
114
Annabelle Fowler retweeted
Some thoughts on how #COVID19 may affect the readiness of the U.S. armed forces with my @MIT_SSP teammate @racheltecott in @monkeycageblog / @washingtonpost.
How will the coronavirus pandemic affect U.S. military readiness — and national security? wapo.st/2U0ZHIm
3
10
Thanks for the shoutout, @ashecon! A new version of my JMP is up, reflecting awesome comments I've received over the past few weeks: scholar.harvard.edu/files/af… And of course, big thanks to my outstanding committee @arieldora @JMichaelMcW @Cutler_econ and Tom McGuire
2
1
15
Thanks @PORTAL_Research! Great to present to a crowd with such deep pharma + regulatory policy expertise
Nice presentation from @AbelleFowler @harvardmed @HMSHCP on her new paper Hurry Up or Wait?: Strategic Delay in the Introduction of Pharmaceutical Line Extensions!
1
12
Nice presentation from @AbelleFowler @harvardmed @HMSHCP on her new paper Hurry Up or Wait?: Strategic Delay in the Introduction of Pharmaceutical Line Extensions!
Annabelle Fowler retweeted
PhD students, are you on the job market? Then join us for the webinar "Strategies (and Encouragement) for Ph.D. Health Economists on the Job Market" with @cawley_john on December 4th from 12pm-1:30pm EST! Sign-up here: https://nitter.gq/t.co/OlVxVQCXat #econtwitter #economics #healthecon
1
31
12
43
Terrific to be back! Thanks @middecon for having me and thanks to all who attended.
It's always a special day when one of @middecon's own returns to present her own research. In this case, @AbelleFowler, who is on the market this winter from the Health Policy program at Harvard, presented work on pharma line extensions: scholar.harvard.edu/afowler/… (Hire her!)
3
19
Annabelle Fowler retweeted
If anyone ever asks you why your choice of y-axis scale matters...
19
106
16
716
When brand switches drug, encourages docs to prescribe new, & offers no reason other than harming generics, antitrust liability should be on table. Shadowen & I explain why liability in product-hopping cases applies to more than deception or sham conduct. https://nitter.gq/t.co/kPDz0szewB
2
8
Annabelle Fowler retweeted
Fascinating analyses from @46brooklyndata drugch.nl/2IxB8yl (1) #PBMs set #generic #drug prices in #Medicaid managed care, contra @pcmanet (2) #Pharmacies earn big profits on some #Medicaid #prescriptions, e.g., #imatinib = $5,290 per Rx, sildenafil = $471 per Rx
7
8
2
11
I'm an unabashed fan of @TheEconomist headline puns, but this one is just 🤦🏻‍♀️🤦🏻‍♀️🤦🏻‍♀️
1
4
I've been following @hannahdreier since she was on the ground covering Venezuela. She's a terrific journalist who continues to report on such important issues. Congratulations!
NEW: The Pulitzer Prize Board just announced that three articles in our series on MS-13 by reporter @hannahdreier have won the 2019 Pulitzer Prize for feature writing. The award is the fifth Pulitzer Prize for ProPublica. propub.li/2UEPELe
1
Ever wonder why it's so hard to pass reasonable legislation lowering drug prices?
PhRMA spent a record-breaking $27.5 million on lobbying in 2018, new filings show buff.ly/2W8dE6u
6
8
Annabelle Fowler retweeted
STAT Plus: How often is a patent granted for more than marginal improvement? You might be surprised. buff.ly/2O0ycII
1
2
Annabelle Fowler retweeted
Justice Department antitrust enforcers cleared CVS’s acquisition of Aetna after the companies took steps to ease regulators’ concerns on.wsj.com/2CCLhaf
7
24
4
33